Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive
neuromyelitis optica spectrum disorder: phase 3 PREVENT study.
Neuromyelitis optica and non-organ specific autoimmunity.
Neuromyelitis optica: a positive appraisal of seronegative cases.
Aquaporin-4 antibodies (NMO-IgG) as a serological marker of
neuromyelitis optica: a critical review of the literature.
Other monophasic subtypes include monophasic
neuromyelitis optica spectrum diseases (NMOSDs) accompanied by optic neuritis and/or transverse myelitis [9, 12, 17, 18], as well as clinically isolated syndromes [optic neuritis (ON), transverse myelitis (TM), cerebellitis, and brainstem disease], which present after puberty and do not confer risk factors for further MS-like episodes, such as positive oligoclonal bands (OCBs) or MS-like lesions on MRI [9, 10, 12, 16].
Neuromyelitis optica (NMO), or Devic's disease, is a rare autoinflammatory demyelinating disease of the optic nerves and spinal cord, characterized by optic neuritis and longitudinally extensive transverse myelitis [1,2].
showed that four polymorphisms (rs7528684, rs945635, rs3761959, and rs2282284) in FCRL3 gene can increase the risk for
neuromyelitis optica (NMO) [34].
Neuromyelitis optica (NMO), also known as Devic's disease, is a central nervous system (CNS) autoimmune disease that preferentially affects the spinal cord and optic nerve [1].
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic autoimmune demyelinating disease of the CNS, usually of the optic nerve and spinal cord, that is associated with serum anti-aquaporin-4 (AQP4) immunoglobulin G antibodies, which have a sensitivity of 60~70% and specificity of 99% for the disease.
Test results were negative for autoantibodies (antinuclear antibodies; c and p antineutrophil cytoplasmic antibodies; double-stranded DNA antibodies; and antiphospholipid, onconeural, and
neuromyelitis optica [antiaquaporin 4] autoantibodies).